Zynerba Pharmaceuticals

Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology

DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) announced the presentation of a poster at the 61st Annual Meeting of the American College of Neuropsychopharmacology, being held December 4-7, 2022 in …

Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology Read More



Zynerba Pharmaceuticals

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome

DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) presented a poster at the recent 2022 National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit in Washington, …

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome Read More